Liraglutide Shows Promise in Pediatric Obesity, While Oncology Trials Face Setbacks
Novo Nordisk's liraglutide demonstrated a significant reduction in BMI in a Phase III trial involving children aged 6-11, showing potential for pediatric obesity treatment.
© Copyright 2025. All Rights Reserved by MedPath